Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
MAGEA6 Biologics Sequence Review Report 2026: Melanoma-associated antigen 6 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEA6 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGEA4 Biologics Sequence Review Report 2026: Melanoma-associated antigen 4 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEA4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGEA3 Biologics Sequence Review Report 2026: Melanoma-associated antigen 3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEA3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGEA2 Biologics Sequence Review Report 2026: Melanoma-associated antigen 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEA2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGEA12 Biologics Sequence Review Report 2026: Melanoma-associated antigen 12 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEA12 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGEA11 Biologics Sequence Review Report 2026: Melanoma-associated antigen 11 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEA11 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGEA1 Biologics Sequence Review Report 2026: Melanoma-associated antigen 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEA1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
LY96 Biologics Sequence Review Report 2026: Lymphocyte antigen 96 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of LY96 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
LY75 Biologics Sequence Review Report 2026: Lymphocyte antigen 75 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of LY75 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
LY6G6F Biologics Sequence Review Report 2026: Lymphocyte antigen 6 complex locus protein G6f Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of LY6G6F sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
LY6G5C Biologics Sequence Review Report 2026: Lymphocyte antigen 6 complex locus protein G5c Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of LY6G5C sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
LY6D Biologics Sequence Review Report 2026: Lymphocyte antigen 6D Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of LY6D sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
880
881
882
883
884
>>
2926
>